At the 2026 Veeva R&D and Quality Summit in Copenhagen, Veeva Systems laid out its most ambitious AI roadmap to date. Rik Van Mol, Senior Vice President of R&D and Quality at Veeva Systems, and Jim Reilly, President of Development Cloud and Executive Vice President of Global Strategy, anchored a keynote that introduced three distinct AI product lines and a slate of new platform features. The announcements affect every major area of drug development — from trial management to regulatory submissions to safety case processing.
The Shift to Agentic Architecture
Veeva’s central argument is that enterprise software architecture must evolve. Applications can no longer function as passive systems of record. They need to support AI agents that actively complete tasks alongside human users.
Veeva calls this framework MAAP — Models, Agents, and Applications. Models handle reasoning. Agents sit outside applications and act on them. Applications remain the core systems of record. Veeva’s strategy is to make Vault “dual mode,” meaning it can be controlled by both human users and AI agents.
The company has been building toward this for two years. Safety and quality agents are already live. Clinical and regulatory agents arrive in August with the 26R2 release.
Three New AI Capabilities Announced
Veeva announced Vault AI, Falcon, and Agentic Authoring as distinct but connected products.
Vault AI embeds agents directly into the Vault platform. Current capabilities include document chat, translation, summarization, document comparison, and query functions. Application-specific agents are live in safety for case narrative generation and in quality for deviation and complaint summaries. In August, users will gain an AI Tab — a ChatGPT-style interface that routes queries to the appropriate agent within Vault. Unlike general AI tools, it operates only on data within the user’s Vault and respects existing security permissions.
Falcon is an entirely new platform that sits outside Vault and delivers what Veeva calls “agentic labor.” These are standardized agents designed to automate high-volume, repetitive workflows end to end. The first three Falcon agents will automate TMF document intake and quality checking, safety case intake and processing, and health authority interaction management — including extracting information from regulatory communications and drafting responses. Falcon is targeting late 2026 availability for early adopters.
Agentic Authoring is a new application that proactively drafts submissible documents. It integrates natively with Vault RIM and Microsoft Word, monitors incoming data, and initiates drafting when conditions are met. This capability is expected in late 2027.
New Products Across Safety, Regulatory, Quality, and Clinical
Beyond AI, Veeva announced several product launches and expansions. In safety, two customers — one top-20 pharma and one enterprise biopharma — are already live on Workbench and Signal, which consolidate case processing and signal detection onto a single platform, replacing legacy systems that had fragmented clinical and global health data.
In regulatory, a new labeling suite is targeting early 2027 for early adopter availability. It manages the complexity between core and local labels to reduce compliance risk at market launch.
Batch Release in quality now has five customers live and eight in implementation. The application connects release decisions directly to Vault RIM, enabling real-time checks on which markets a product is registered in. BioNTech and Sobe are among the live customers.
On the clinical side, Site CTMS launched earlier this year and already supports over 65 active studies. Veeva is adding eSource, which will integrate site EHR systems with sponsor EDC to eliminate duplicate data entry. Early adopters are expected by year-end.
CRA Central, a unified command center for clinical research associates, will consolidate EDC, RTSM, and monitoring visit workflows into a single interface. Its first release is planned for this year.
Platform Investment and What Comes Next
Veeva reported over 4,000 active Vault instances in production and more than 2 million monthly active users. That scale is driving investment in core platform performance — specifically search speed, page loads, and navigation responsiveness.
Two platform capabilities are coming this year. In-Vault redaction will allow users to remove PHI or confidential information without exporting documents to third-party tools — a significant compliance improvement. A redesigned Doc Viewer, one of the oldest and most-used parts of Vault with over 5 million document views per day, arrives in August. It adds side-by-side document comparison, AI-generated difference summaries, and a personalized search that learns from user behavior.
The August 26R2 release is the clearest near-term milestone. It brings Vault AI to all customers, delivers the AI Tab, and launches the first clinical and regulatory agents. For organizations planning AI adoption in drug development, that release marks the practical entry point into Veeva’s agentic ecosystem.
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
